Conba Pharma Advances on Approval for New Drug Technology: Shanghai Mover

Zhejiang Conba Pharmaceutical Co. (600572) shares rose the most in more than eight months after the Chinese government approved its extraction technology used in making drugs for cardiovascular disease.

The stock jumped 7.2 percent to 8.79 yuan at the close in Shanghai, the biggest advance since May 31. The benchmark Shanghai Composite Index (SHCOMP) decreased 0.3 percent.

Conba, based in the eastern Chinese province of Zhejiang, received government approval for the technology used in producing a brand of ginkgo leaf capsules, according to a statement to Shanghai’s stock exchange. The company will also receive a 1.96 million yuan ($311,000) subsidy for the project from the government, the statement showed.

“This is good news to the company and will surely help improve its competitiveness and boost its herbal medicine sales,” Liu Yaming, an analyst at Founder Securities Co., said in a phone interview in Shanghai. Liu has a “buy” rating on the stock.

Cardiovascular disease is the biggest killer in China, accounting for 38 percent of deaths, according to the World Health Organization.

Conba, which competes with Kunming Pharmaceutical Corp. (600422), probably sold 50 percent more ginkgo leaf tablets with sales of 100 million yuan in 2011 from a year earlier, Founder Securities’ Liu said.

Kunming Pharmaceutical fell for the first time in five days, losing 1.5 percent to 13.95 yuan in Shanghai. The shares have dropped 6.1 percent this year, compared with a 24 percent rally in Conba.

--Jiang Jianguo. Editor: Bloomberg News, Linus Chua

To contact the reporter on this story: Jiang Jianguo in Shanghai at jjiang@bloomberg.net

To contact the editor responsible for this story: Bloomberg News at schen37@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.